Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation
Graphical abstract
Highlights
► Recombinant therapeutic protein production is a multibillion dollar market. ► E. coli comprises 30% of recombinant protein production but not suitable for human therapeutics. ► Eukaryotic systems other than yeast are costly or not so efficient regarding protein yields. ► S. cerevisiae shows a high potential to be a suitable platform for therapeutic proteins. ► Human blood proteins are the next candidates to be challenged by S. cerevisiae system.
Introduction
Microorganisms have been extensively used since ancient times for the production of fermented food and beverages, thousands of years before the actual nature of the fermentative processes was known. In the early 20th century the production of citric acid based on microbial fermentation was initiated as the first large scale fermentation product and this was followed by industrial production of penicillin as the first antibiotic. Introduction of the genetic engineering in the 1970s paved the way for the establishment and development of the current biotech industry, allowing the commercial production of industrial enzymes and biopharmaceutical proteins. In 1980, the FDA approved for clinical use the recombinant insulin obtained from Escherichia coli, becoming the first recombinant pharmaceutical protein to enter the market [1••]. Since then, the biotechnology industry has grown substantially, and currently about 25% of commercial pharmaceuticals are biopharmaceuticals [2] with 2010 sales exceeding USD100 billions [3]. About half of the world-wide sales are in the USA with monoclonal antibodies representing the majority (>USD18 billions) followed by hormones (USD11 billions) and growth factors (>USD10 billions) [4]. Together with the production of industrial enzymes, the recombinant protein production market is expected to rise to 169 billion dollars in 2014 [3] (Figure 1).
Section snippets
Platforms for production of pharmaceutical proteins
Industrial biotechnology has traditionally used numerous bacterial and eukaryal cells as production platforms, with the main criterion for host selection being the ability to produce the desired compound. However, with the advent of genetic engineering it became possible to introduce heterologous genes and create new traits in non-natural producers, allowing the development of cell factories for the production of chemicals through metabolic engineering. E. coli was the earliest platform to be
How to make S. cerevisiae a better producer of pharmaceutical proteins?
The technology for industrial production of recombinant pharmaceutical proteins in S. cerevisiae is well established and currently applied for production of human insulin, hepatitis virus vaccines and human papilloma virus vaccines, and its potential to be used for large scale production of many other proteins in the forthcoming years is therefore high. Furthermore, the advent of systems biology allowing global metabolism analysis and the application of so-called ‘omics’ approaches such as
Production of recombinant human blood proteins
Among the 58 biopharmaceuticals approved in the United States and/or Europe from 2006 to 2010 four are blood related proteins, including a rh coagulation factor VIII produced in CHO cells, a rh antithrombin from milk of transgenic goats, a plasma kallikrein inhibitor produced in Pichia pastoris, and a rh thrombin produced in CHO cells [27•]. All have therapeutic use for treatment of hemophilia. To date, most of the recombinant blood related biopharmaceuticals approved for clinical treatment are
S. cerevisiae as a cell factory for human hemoglobin production
All the proteins described above are blood plasma components which contribute to different roles of blood such as coagulation, clotting, transport of iron, maintain blood osmotic pressure, and blood volume. The additional crucial role of blood is the transport of oxygen and the only component in blood that possesses oxygen carrier function is hemoglobin (found in erythrocytes), and this is therefore a key component for development of human blood substitutes for treatment of patients with
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
We would like to thank Zihe Liu and Dr. Jin Hou for suggestions and comments on the manuscript. This work has been funded by the Chalmers Foundation, European Research Council project INSYSBIO (Grant no. 247013) and the Novo Nordisk Foundation.
References (67)
- et al.
Production of recombinant proteins by yeast cells
Biotechnol Adv
(2012) Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
Nat Biotechnol
(2004)- et al.
Engineering of vesicle trafficking improves heterologous protein secretion in Saccharomyces cerevisiae
Metab Eng
(2012) - et al.
Engineering of mucin-type human glycoproteins in yeast cells
Proc Natl Acad Sci U S A
(2008) - et al.
Expression of fully functional tetrameric human hemoglobin in Escherichia coli
Proc Natl Acad Sci U S A
(1990) - et al.
A human recombinant haemoglobin designed for use as a blood substitute
Nature
(1992) - et al.
Structure of oxidized α-haemoglobin bound to AHSP reveals a protective mechanism for haem
Nature
(2005) - et al.
High-yield expression in Escherichia coli of soluble human {alpha}-hemoglobin complexed with its molecular chaperone
Protein Eng Des Sel
(2006) - et al.
Effects of beta 6 aromatic amino acids on polymerization and solubility of recombinant hemoglobins made in yeast
J Biol Chem
(1993) - et al.
Heme biosynthesis and its regulation: towards understanding and improvement of heme biosynthesis in filamentous fungi
Appl Microbiol Biotechnol
(2011)
Production of antithrombotic hirudin in GAL1-disrupted Saccharomyces cerevisiae
Appl Microbiol Biotechnol
Expression, purification, and characterization of humanized anti-HBs Fab fragment
J Biochem
High-level secretion of correctly processed recombinant human interleukin-1 beta in Kluyveromyces lactis
Gene
High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation
J Biosci Bioeng
Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin
Microb Cell Fact
Microbial factories forrecombinant pharmaceuticals
Microb Cell Fact
Cumulative updating of approved biopharmaceuticals
Hum Antibodies
Market watch: sales of biologics to show robust growth through to 2013
Nat Rev Drug Discov
What's fueling the biotech engine — 2010 to 2011
Nat Biotechnol
Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems
Appl Microbiol Biotechnol
Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli
Adv Biochem Eng Biotechnol
Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems?
Appl Microbiol Biotechnol
PVL: high yield production of heterologous proteins with Escherichia coli
Defence Sci J
Post-translational modifications in the context of therapeutic proteins
Nat Biotechnol
Engineering of glycosylation in yeast and other fungi: current state and perspectives
Appl Microbiol Biotechnol
Dynamic model for CHO cell engineering
J Biotechnol
Improving protein production processes
Gen Eng News
Recombinant protein vaccines produced in insect cells
Vaccine
Production of recombinant proteins by microbes and higher organisms
Biotechnol Adv
Engineering of a mammalian O-glycosylation pathway in the yeast Saccharomyces cerevisiae: production of O-fucosylated epidermal growth factor domains
Glycobiology
Yeast systems biotechnology for the production of heterologous proteins
FEMS Yeast Res
A systems-level approach for metabolic engineering of yeast cell factories
FEMS Yeast Res
Opportunities for yeast metabolic engineering: lessons from synthetic biology
Biotechnol J
Cited by (67)
Microbiology of biofuels: Cultivating the future
2022, Relationship between Microbes and the Environment for Sustainable Ecosystem Services: Microbial Tools for Sustainable Ecosystem Services: Volume 3Biotechnology applications in infectious disease
2022, Biotechnology in Healthcare, Volume 2: Applications and InitiativesHepatitis B core-based virus-like particles: A platform for vaccine development in plants
2021, Biotechnology ReportsEngineering and optimization of phosphate-responsive phytase expression in Pichia pastoris yeast for phytate hydrolysis
2020, Enzyme and Microbial TechnologyTrichoderma-functional metabolomics to genetic engineering
2020, New and Future Developments in Microbial Biotechnology and Bioengineering: Recent Developments in Trichoderma Research
- 3
These authors contributed equally to this article.